PMID- 29095568
OWN - NLM
STAT- MEDLINE
DCOM- 20190111
LR  - 20221207
IS  - 1463-1326 (Electronic)
IS  - 1462-8902 (Print)
IS  - 1462-8902 (Linking)
VI  - 20
IP  - 4
DP  - 2018 Apr
TI  - Direct head-to-head comparison of glycaemic durability of dipeptidyl peptidase-4 
      inhibitors and sulphonylureas in patients with type 2 diabetes mellitus: A 
      meta-analysis of long-term randomized controlled trials.
PG  - 1029-1033
LID - 10.1111/dom.13147 [doi]
AB  - We performed a meta-analysis of randomized controlled trials (RCTs) to compare 
      the long-term glycaemic durability of dipeptidyl-peptidase 4 (DPP-4) inhibitors 
      vs that of sulphonylureas (SUs) in patients with type 2 diabetes mellitus (T2DM), 
      in terms of the changes in glycated haemoglobin (HbA1c) levels from an 
      intermediate time point (26 or 52 weeks) to 104 weeks of treatment. The Medline 
      (PubMed), Embase (Ovid), and CENTER (Cochrane Library) databases were searched 
      for relevant RCTs. Eight RCTs were included. Compared with SUs, DPP-4 inhibitors 
      were associated with significantly smaller increases in the HbA1c level from 24 
      to 28 weeks to 104 weeks (mean difference [MD]: -0.16%, 95% confidence interval 
      [CI]: -0.21 to -0.11; P < .001) and from 52 weeks to 104 weeks (MD -0.06%, 95% CI 
      -0.10 to -0.02; P = .001). No significant heterogeneities were detected among the 
      included comparisons (I(2)  = 0%). These results suggest that long-term treatment 
      with DPP-4 inhibitors confers better durability of glycaemic response than 
      treatment with SUs in patients with T2DM, which may indicate that DPP-4 
      inhibitors better preserve islet beta-cell function compared with SUs.
CI  - (c) 2017 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & 
      Sons Ltd.
FAU - Chen, Kang
AU  - Chen K
AD  - Department of Endocrinology, Chinese PLA General Hospital, Beijing, China.
FAU - Kang, Deying
AU  - Kang D
AD  - Department of Evidence-based Medicine and Clinical Epidemiology, West China 
      Hospital, Sichuan University, Chengdu, China.
FAU - Yu, Miao
AU  - Yu M
AD  - Department of Endocrinology, Key Laboratory of Endocrinology, Ministry of Health, 
      Peking Union Medical College Hospital, Diabetes Research Centre of Chinese 
      Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
FAU - Zhang, Ruya
AU  - Zhang R
AD  - Medical Affairs, MSD China Holding Company, Shanghai, China.
FAU - Zhang, Ye
AU  - Zhang Y
AD  - Medical Affairs, MSD China Holding Company, Shanghai, China.
FAU - Chen, Guojuan
AU  - Chen G
AD  - Medical Affairs, MSD China Holding Company, Shanghai, China.
FAU - Mu, Yiming
AU  - Mu Y
AUID- ORCID: 0000-0002-3344-3540
AD  - Department of Endocrinology, Chinese PLA General Hospital, Beijing, China.
LA  - eng
PT  - Comparative Study
PT  - Journal Article
PT  - Meta-Analysis
PT  - Research Support, Non-U.S. Gov't
DEP - 20171205
PL  - England
TA  - Diabetes Obes Metab
JT  - Diabetes, obesity & metabolism
JID - 100883645
RN  - 0 (Blood Glucose)
RN  - 0 (Dipeptidyl-Peptidase IV Inhibitors)
RN  - 0 (Glycated Hemoglobin A)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Sulfonylurea Compounds)
SB  - IM
MH  - Blood Glucose/*drug effects/metabolism
MH  - Diabetes Mellitus, Type 2/blood/*drug therapy/epidemiology
MH  - Dipeptidyl-Peptidase IV Inhibitors/*therapeutic use
MH  - Female
MH  - Glycated Hemoglobin/drug effects/metabolism
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Male
MH  - Middle Aged
MH  - Randomized Controlled Trials as Topic/statistics & numerical data
MH  - Sulfonylurea Compounds/*therapeutic use
MH  - Time Factors
PMC - PMC5873267
OTO - NOTNLM
OT  - dipeptidyl peptidase-4 inhibitors
OT  - glycaemic durability
OT  - glycated haemoglobin
OT  - meta-analysis
OT  - sulphonylureas
COIS- G. C., Y. Z. and R. Z. are employees of MSD China Holding Co., Ltd.
EDAT- 2017/11/03 06:00
MHDA- 2019/01/12 06:00
PMCR- 2018/03/28
CRDT- 2017/11/03 06:00
PHST- 2017/08/14 00:00 [received]
PHST- 2017/10/12 00:00 [revised]
PHST- 2017/10/29 00:00 [accepted]
PHST- 2017/11/03 06:00 [pubmed]
PHST- 2019/01/12 06:00 [medline]
PHST- 2017/11/03 06:00 [entrez]
PHST- 2018/03/28 00:00 [pmc-release]
AID - DOM13147 [pii]
AID - 10.1111/dom.13147 [doi]
PST - ppublish
SO  - Diabetes Obes Metab. 2018 Apr;20(4):1029-1033. doi: 10.1111/dom.13147. Epub 2017 
      Dec 5.